News | Nuclear Imaging | November 07, 2018

New market report notes that approximately $10 billion in M&A transactions have occurred over the past four years, with signs indicating continuing future growth

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine

November 7, 2018 — With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry towards radiopharmaceuticals and in particular radiotherapeutics and radiotheranostics is clearly growing, as foreseen a few years ago by MEDraysintell.

Numerous major acquisitions have involved the conventional pharmaceutical industry over the past four years:

  • In 2014, Bayer acquired Algeta ASA and its major drug for end-stage prostate cancer treatment 223Ra-Xofigo for about NOK 17.6 billion ($2.9 billion), while Novartis took over Advanced Accelerator Applications (AAA) and its Neuro Endocrine Tumor treatment 177Lu-Lutathera in January 2018 for a total value of $3.9 billion;
  • Additionally Novartis announced in October 2018 the acquisition of the company Endocyte developing the prostate cancer drug 177Lu-PSMA-617 for a total value of $2.1 billion. This transaction is expected to be completed in the first half of 2019.
  • Ipsen Pharma acquired in May 2015 the German company OctreoPharm Sciences GmbH, for a total of EUR 50 million (about $55 million) and one year later a large part of the radiopharmaceutical pipeline of the German company 3B Pharmaceuticals GmbH; and
  • Sun Pharmaceutical Industries acquired Pharmalucence in July 2014 for an undisclosed amount.

MEDraysintell noted that other mergers within the radiopharmaceutical industry showed consolidation of this industry:

  • IBA Molecular acquired the Nuclear Medicine business of Mallinckrodt in January 2017 for a total of about $690 million;
  • Jubilant Draximage acquired the Triad Isotopes radiopharmacy network in May 2017; and
  • Sofie Biosciences took over Zevacor Pharma in May 2017.

The company said there are great chances that additional mergers and acquisitions (M&A) will take place within the next 12 months. At the same time, the conventional pharmaceutical industry is now looking for new opportunities in early-stage research programs in this area. MEDraysintell anticipates that the global market will reach $5.9 billion in 2019, and it is now expected that radiotherapeutics will represent more than 60 percent of the $26 billion nuclear medicine market by 2030.

Most of the development of new radiopharmaceuticals is performed by new medium-sized radiopharmaceuticals companies and conventional pharmaceutical corporations. MEDraysintell said these companies are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018.

For more information: www.medraysintell.com


Related Content

News | Breast Imaging

May 25, 2023 — GE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN ...

Time May 25, 2023
arrow
News | Radiation Oncology

May 16, 2023 — The American Society for Radiation Oncology (ASTRO) today expressed its strong support for President ...

Time May 16, 2023
arrow
News | Contrast Media

May 16, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

Time May 16, 2023
arrow
News | Contrast Media

May 15, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced that ...

Time May 15, 2023
arrow
News | PET Imaging

May 12, 2023 — A newly published meta-analysis indicates that amino acid PET can accurately differentiate recurrent or ...

Time May 12, 2023
arrow
News | Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
News | Radiation Therapy

May 1, 2023 — Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage ...

Time May 01, 2023
arrow
News | PET Imaging

April 28, 2023 — GE HealthCare to deliver two Cyclotrons next year, expanding South Africa’s capacity to produce ...

Time April 28, 2023
arrow
News | Radiopharmaceuticals and Tracers

April 24, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 24, 2023
arrow
News | Molecular Imaging

April 13, 2023 —NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 13, 2023
arrow
Subscribe Now